Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

Aridis Pharmaceuticals, Inc.: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Armistice Capital, LLC amended its Schedule 13G filing with the SEC covering its stake in Aridis Pharmaceuticals, Inc., under accession number 0001172661-26-005210. The filing is a passive-investor ownership update rather than a change in control, and the amended disclosure revises the fund's reported position in the pharmaceutical company. The update matters because 13G amendments signal shifts in institutional ownership that can affect liquidity and shareholder composition in a small-cap stock. Investors will watch for the specific share count and percentage disclosed in the amendment, and for any further 13G or 13D filings that would indicate a more active stance.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Armistice Capital, LLC, Aridis Pharmaceuticals, Inc.